vs
Side-by-side financial comparison of BillionToOne, Inc. (BLLN) and Nano Dimension Ltd. (NNDM). Click either name above to swap in a different company.
BillionToOne, Inc. is the larger business by last-quarter revenue ($83.5M vs $57.8M, roughly 1.4× Nano Dimension Ltd.). BillionToOne, Inc. runs the higher net margin — 6.8% vs -171.1%, a 177.9% gap on every dollar of revenue. BillionToOne, Inc. produced more free cash flow last quarter ($6.5M vs $-21.1M).
BillionToOne, Inc. is a life sciences and molecular diagnostics firm developing high-precision genetic testing solutions. Its core offerings include non-invasive prenatal tests, oncology diagnostics, and rare disease screening, serving clinical providers and patients mainly in North America.
Nano Dimension Ltd. is a leading provider of additively manufactured electronics solutions and 3D printing technologies. It designs high-precision 3D printers, related materials, and software for producing printed circuit boards, microelectronics components, and multi-layer electronic devices, serving aerospace, defense, medical, automotive, and industrial electronics segments across global markets.
BLLN vs NNDM — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2024
| Metric | | |
|---|---|---|
| Revenue | $83.5M | $57.8M |
| Net Profit | $5.7M | $-98.8M |
| Gross Margin | 69.9% | 43.1% |
| Operating Margin | 11.5% | -155.1% |
| Net Margin | 6.8% | -171.1% |
| Revenue YoY | 117.4% | — |
| Net Profit YoY | 138.3% | — |
| EPS (diluted) | $0.10 | $-0.45 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | $83.5M | — | ||
| Q4 24 | — | $57.8M | ||
| Q3 24 | $38.4M | — | ||
| Q2 24 | — | $28.4M | ||
| Q2 23 | — | $29.7M |
| Q3 25 | $5.7M | — | ||
| Q4 24 | — | $-98.8M | ||
| Q3 24 | $-14.9M | — | ||
| Q2 24 | — | $-79.2M | ||
| Q2 23 | — | $12.6M |
| Q3 25 | 69.9% | — | ||
| Q4 24 | — | 43.1% | ||
| Q3 24 | 52.6% | — | ||
| Q2 24 | — | 45.8% | ||
| Q2 23 | — | 44.0% |
| Q3 25 | 11.5% | — | ||
| Q4 24 | — | -155.1% | ||
| Q3 24 | -32.9% | — | ||
| Q2 24 | — | — | ||
| Q2 23 | — | — |
| Q3 25 | 6.8% | — | ||
| Q4 24 | — | -171.1% | ||
| Q3 24 | -38.8% | — | ||
| Q2 24 | — | -279.4% | ||
| Q2 23 | — | 42.3% |
| Q3 25 | $0.10 | — | ||
| Q4 24 | — | $-0.45 | ||
| Q3 24 | $-1.47 | — | ||
| Q2 24 | — | $-0.35 | ||
| Q2 23 | — | $0.05 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $195.2M | $317.2M |
| Total DebtLower is stronger | $55.0M | — |
| Stockholders' EquityBook value | $-239.5M | $860.0M |
| Total Assets | $327.5M | $902.5M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $195.2M | — | ||
| Q4 24 | — | $317.2M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $231.8M | ||
| Q2 23 | — | $454.6M |
| Q3 25 | $55.0M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q2 23 | — | — |
| Q3 25 | $-239.5M | — | ||
| Q4 24 | — | $860.0M | ||
| Q3 24 | $-242.9M | — | ||
| Q2 24 | — | $870.3M | ||
| Q2 23 | — | $1.1B |
| Q3 25 | $327.5M | — | ||
| Q4 24 | — | $902.5M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $911.0M | ||
| Q2 23 | — | $1.2B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $13.8M | $-18.9M |
| Free Cash FlowOCF − Capex | $6.5M | $-21.1M |
| FCF MarginFCF / Revenue | 7.7% | -36.5% |
| Capex IntensityCapex / Revenue | 8.8% | 3.8% |
| Cash ConversionOCF / Net Profit | 2.42× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $13.8M | — | ||
| Q4 24 | — | $-18.9M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $-30.7M | ||
| Q2 23 | — | $-56.1M |
| Q3 25 | $6.5M | — | ||
| Q4 24 | — | $-21.1M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q2 23 | — | — |
| Q3 25 | 7.7% | — | ||
| Q4 24 | — | -36.5% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q2 23 | — | — |
| Q3 25 | 8.8% | — | ||
| Q4 24 | — | 3.8% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q2 23 | — | — |
| Q3 25 | 2.42× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q2 23 | — | -4.47× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BLLN
| Prenatal | $74.1M | 89% |
| Oncology | $8.7M | 10% |
NNDM
Segment breakdown not available.
